Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome

verfasst von: Ming Wu, Ding-yang Liu, Xian-rui Yuan, Qing Liu, Xin-jun Jiang, Dun Yuan, Jun Huang, Xue-jun Li, Zhi-quan Yang

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Moesin, a member of the ERM family, acts as a linker between the actin cytoskeleton and the plasma membrane and plays a key role in the control of cell morphology, motility, adhesion and other processes of tumourigenesis. The expression pattern and clinical significance of moesin in astrocytoma remain unknown. In this study, we used RT-PCR to systematically investigate the expression of moesin in 49 astrocytomas of different pathological grade and 6 normal brain tissues. We found that the mRNA expression levels of moesin in astrocytomas were significantly higher in comparison with normal brain tissues. Furthermore, moesin up-regulation was correlated with pathological grade of astrocytomas. Subsequently, we tested 112 astrocytomas and 14 normal brain tissues by immunohistochemistry. Similar results were also confirmed. Univariate and multivariate survival analysis were used to determine the correlations of moesin expression with overall survival and progression-free survival. Our results showed the expression of moesin was strongly negatively correlated with the patient progression-free survival and overall survival. These results suggest moesin protein involved in the genesis and progression of astrocytomas and might be regarded as an independent predictor of poor prognosis.
Literatur
1.
Zurück zum Zitat Lefranc F, Rynkowski M, DeWitte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009;34:3–35.PubMedCrossRef Lefranc F, Rynkowski M, DeWitte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009;34:3–35.PubMedCrossRef
2.
Zurück zum Zitat Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108(9):3749–54.PubMedCrossRef Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108(9):3749–54.PubMedCrossRef
3.
Zurück zum Zitat Pham MH, Zada G, Mosich GM, Chen TC, Giannotta SL, Wang K, et al. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus. 2011;30(5):E7.PubMed Pham MH, Zada G, Mosich GM, Chen TC, Giannotta SL, Wang K, et al. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus. 2011;30(5):E7.PubMed
4.
Zurück zum Zitat Tsukita S, Yonemura S. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci. 1997;22(2):53–8.PubMedCrossRef Tsukita S, Yonemura S. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci. 1997;22(2):53–8.PubMedCrossRef
5.
Zurück zum Zitat Speck O, Hughes SC, Noren NK, Kulikauskas RM, Fehon RG. Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature. 2003;421(6918):83–7.PubMedCrossRef Speck O, Hughes SC, Noren NK, Kulikauskas RM, Fehon RG. Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature. 2003;421(6918):83–7.PubMedCrossRef
6.
Zurück zum Zitat Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11(1):109–16.PubMedCrossRef Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11(1):109–16.PubMedCrossRef
7.
Zurück zum Zitat Hua D, Ding D, Han X, Zhang W, Zhao N, Foltz G, et al. Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. Oncol Rep. 2012;27(3):700–6.PubMed Hua D, Ding D, Han X, Zhang W, Zhao N, Foltz G, et al. Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. Oncol Rep. 2012;27(3):700–6.PubMed
8.
Zurück zum Zitat Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182–6.PubMedCrossRef Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182–6.PubMedCrossRef
9.
Zurück zum Zitat Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein six-1 as key metastatic regulators. Nat Med. 2004;10(2):175–81.PubMedCrossRef Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein six-1 as key metastatic regulators. Nat Med. 2004;10(2):175–81.PubMedCrossRef
10.
Zurück zum Zitat Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005;7(3):R365–73.PubMedCrossRef Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005;7(3):R365–73.PubMedCrossRef
11.
Zurück zum Zitat Okamura D, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, et al. Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection. Mod Pathol. 2008;21(7):847–55.PubMedCrossRef Okamura D, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, et al. Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection. Mod Pathol. 2008;21(7):847–55.PubMedCrossRef
12.
Zurück zum Zitat Carmeci C, Thompson DA, Kuang WW, Lightdale N, Furthmayr H, Weigel RJ. Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype. Surgery. 1998;124(2):211–7.PubMedCrossRef Carmeci C, Thompson DA, Kuang WW, Lightdale N, Furthmayr H, Weigel RJ. Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype. Surgery. 1998;124(2):211–7.PubMedCrossRef
13.
Zurück zum Zitat Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007;121(8):1779–85.PubMedCrossRef Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007;121(8):1779–85.PubMedCrossRef
14.
Zurück zum Zitat Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009;124(7):1614–21.PubMedCrossRef Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009;124(7):1614–21.PubMedCrossRef
15.
Zurück zum Zitat Estecha A, Sanchez-Martin L, Puig-Kroger A, Bartolome RA, Teixido J, Samaniego R, et al. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009;122(Pt 19):3492–501.PubMedCrossRef Estecha A, Sanchez-Martin L, Puig-Kroger A, Bartolome RA, Teixido J, Samaniego R, et al. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009;122(Pt 19):3492–501.PubMedCrossRef
16.
Zurück zum Zitat Li YJ, Tao XF, He Y, Fu H. Expression of ezrin, moesin in the gastric carcinoma and its clinical significance. Chin J Cancer. 2007;16:550–2. Li YJ, Tao XF, He Y, Fu H. Expression of ezrin, moesin in the gastric carcinoma and its clinical significance. Chin J Cancer. 2007;16:550–2.
17.
Zurück zum Zitat Ou-Yang M, Liu HR, Zhang Y, Zhu X, Yang Q. ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells. Biochimie. 2011;93(5):954–61.PubMedCrossRef Ou-Yang M, Liu HR, Zhang Y, Zhu X, Yang Q. ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells. Biochimie. 2011;93(5):954–61.PubMedCrossRef
18.
Zurück zum Zitat Morales FC, Molina JR, Hayashi Y, Georgescu MM. Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol. 2010;12(6):528–39.PubMedCrossRef Morales FC, Molina JR, Hayashi Y, Georgescu MM. Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol. 2010;12(6):528–39.PubMedCrossRef
19.
Zurück zum Zitat Osawa H, Smith CA, Ra YS, Kongkham P, Rutka JT. The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells. Neuro Oncol. 2009;11(4):381–93.PubMedCrossRef Osawa H, Smith CA, Ra YS, Kongkham P, Rutka JT. The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells. Neuro Oncol. 2009;11(4):381–93.PubMedCrossRef
20.
Zurück zum Zitat Tynninen O, Carpen O, Jaaskelainen J, Paavonen T, Paetau A. Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol. 2004;30(5):472–7.PubMedCrossRef Tynninen O, Carpen O, Jaaskelainen J, Paavonen T, Paetau A. Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol. 2004;30(5):472–7.PubMedCrossRef
21.
Zurück zum Zitat Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011;104(3):639–46.PubMedCrossRef Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011;104(3):639–46.PubMedCrossRef
22.
Zurück zum Zitat Nabors LB. Targeted molecular therapy for malignant gliomas. Curr Treat Options Oncol. 2004;5(6):519–26.PubMedCrossRef Nabors LB. Targeted molecular therapy for malignant gliomas. Curr Treat Options Oncol. 2004;5(6):519–26.PubMedCrossRef
23.
Zurück zum Zitat Neisch AL, Speck O, Stronach B, Fehon RG. Rho1 regulates apoptosis via activation of the JNK signaling pathway at the plasma membrane. J Cell Biol. 2010;189(2):311–23.PubMedCrossRef Neisch AL, Speck O, Stronach B, Fehon RG. Rho1 regulates apoptosis via activation of the JNK signaling pathway at the plasma membrane. J Cell Biol. 2010;189(2):311–23.PubMedCrossRef
24.
Zurück zum Zitat Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, et al. Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med. 2010;14(5):1166–79.PubMed Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, et al. Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med. 2010;14(5):1166–79.PubMed
25.
Zurück zum Zitat Ichikawa T, Masumoto J, Kaneko M, Saida T, Sagara J, Taniguchi S. Expression of moesin and its associated molecule CD44 in epithelial skin tumors. J Cutan Pathol. 1998;25(5):237–43.PubMedCrossRef Ichikawa T, Masumoto J, Kaneko M, Saida T, Sagara J, Taniguchi S. Expression of moesin and its associated molecule CD44 in epithelial skin tumors. J Cutan Pathol. 1998;25(5):237–43.PubMedCrossRef
26.
Zurück zum Zitat Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics. 2006;7:268.PubMedCrossRef Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics. 2006;7:268.PubMedCrossRef
Metadaten
Titel
The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome
verfasst von
Ming Wu
Ding-yang Liu
Xian-rui Yuan
Qing Liu
Xin-jun Jiang
Dun Yuan
Jun Huang
Xue-jun Li
Zhi-quan Yang
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0372-z

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.